Callan JMB to Oversee Manufacturing, Quality for Attune Biotech's Long COVID IND Trials
Summary
Callan JMB Inc. has been selected to oversee manufacturing and quality control for Attune Biotech's Investigational New Drug (IND) clinical trials for lodonal™ (JKB-122), a drug targeting Long COVID. This engagement includes critical services such as Contract Manufacturing Organization (CMO) qualification, comprehensive batch record review, and supply chain verification. This specific project follows a strategic teaming agreement announced in January 2026, where Callan JMB was established as an independent third-party overseer for Attune's operations. The FDA has received and assigned an IND application number for lodonal™ for Long COVID, a condition with significant unmet medical need. For Callan JMB, a micro-cap company, this represents a concrete revenue-generating contract and a significant validation of its specialized logistics and oversight services within the life sciences sector. Investors will monitor the progress of Attune Biotech's Phase 2b/3 clinical trials for lodonal™ and any further specific engagements or expansions of the partnership.
At the time of this announcement, CJMB was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $1.08 to $6.13. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.